$20.33
0.74% yesterday
Nasdaq, May 20, 10:17 pm CET
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$20.33
+0.26 1.30% 1M
-0.12 0.59% 6M
-0.54 2.59% YTD
-9.36 31.53% 1Y
-10.75 34.59% 3Y
-8.05 28.37% 5Y
+11.59 132.61% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.15 0.74%
ISIN
US3723032062
Symbol
GMAB
Sector

Key metrics

Market capitalization $12.50b
Enterprise Value $9.41b
P/E (TTM) P/E ratio 11.41
EV/FCF (TTM) EV/FCF 8.08
EV/Sales (TTM) EV/Sales 2.91
P/S ratio (TTM) P/S ratio 3.87
P/B ratio (TTM) P/B ratio 2.44
Revenue growth (TTM) Revenue growth 25.11%
Revenue (TTM) Revenue $3.23b
EBIT (operating result TTM) EBIT $1.08b
Free Cash Flow (TTM) Free Cash Flow $1.16b
Cash position $3.23b
EPS (TTM) EPS $1.76
P/E forward 13.40
P/S forward 3.47
EV/Sales forward 2.61
Short interest 0.39%
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Genmab - ADR forecast:

19x Buy
70%
7x Hold
26%
1x Sell
4%

Analyst Opinions

27 Analysts have issued a Genmab - ADR forecast:

Buy
70%
Hold
26%
Sell
4%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3,232 3,232
25% 25%
100%
- Direct Costs 158 158
-
5%
3,074 3,074
-
95%
- Selling and Administrative Expenses 561 561
11% 11%
17%
- Research and Development Expense 1,437 1,437
21% 21%
44%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,076 1,076
30% 30%
33%
Net Profit 1,135 1,135
43% 43%
35%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Neutral
GlobeNewsWire
about 12 hours ago
Company Announcement COPENHAGEN, Denmark; May 20, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 1,746 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Neutral
GlobeNewsWire
one day ago
Company Announcement COPENHAGEN, Denmark; May 19, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Positive
Seeking Alpha
one day ago
Genmab has promising proprietary antibody platforms and partnerships that have helped it transition from licensor to commercial-stage biotech. Their robust royalty stream from Darzalex and Kesimpta funds R&D, while net product sales of epcoritamab and Tivdak are quickly growing as well. Their late-stage pipeline includes epcoritamab label expansions, Rina-S in ovarian cancer, and Acsunilimab in...
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today